Lead Product(s): ATI-2307
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase I Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bloom Burton Securities
Deal Size: $10.2 million Upfront Cash: Undisclosed
Deal Type: Financing February 13, 2020
The net proceeds of the Offering will be used to fund planned research and development activities for the Company’s four product candidates including ATI-2307, ATI-1701, ATI-1503 and ATI-1501.